Genomics, Vertex Extend Drug Discovery Deal Worth More Than $220 Million

Genomics Ltd. and Vertex Pharmaceuticals have extended their drug discovery collaboration by four years under an agreement with a total potential value of more than $220 million. The extension builds on an eight-year collaboration that began in 2018, the same year Vertex took an equity stake in Genomics.

The contract value depends on the achievement of research, development, regulatory and commercial milestones. The agreement also provides for tiered royalties based on future net sales of any products that result from the collaboration.

Scientists from the two companies will continue to use human genetic data to identify potential drug targets and assess whether the evidence supports pursuing them. The work also includes selecting biomarkers for precision medicines and examining the clinical effects of human genetic variation in diseases where treatment needs remain unmet.

Genomics analyzes large-scale genetic and health data through its Mystra platform, which draws on datasets linking genetic variation to observable traits and health outcomes. The company says its data collection includes more than 45,000 genome-wide association studies and that it has used its data and analytical tools to identify more than 100 drug targets across diseases including cancer, heart disease and diabetes.

Genomics was spun out of the University of Oxford in 2014 and has offices in Oxford and London in the United Kingdom and in Research Triangle Park, North Carolina. Its work also includes using genetic and health data to develop tools for predicting disease risk and supporting preventive care.

 

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion